Ofloxacin uses
Reading Document
Medical Text Search
ofloxacin uses indications clinical applications
Medical Text Search
ofloxacin mechanism of action pharmacology dosage
GradeResponse
GradeResponse
Here is a comprehensive overview of Ofloxacin — a second-generation fluoroquinolone antibiotic.
Ofloxacin — Uses & Clinical Applications
Mechanism of Action
Ofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to bacterial cell death (bactericidal action).
Approved / Clinical Uses
1. Urinary Tract Infections (UTIs)
- Uncomplicated and complicated UTIs caused by E. coli, K. pneumoniae, Proteus mirabilis
- Prostatitis (acute bacterial) — ofloxacin is particularly effective due to good tissue penetration
2. Sexually Transmitted Infections (STIs)
- Gonorrhea (Neisseria gonorrhoeae) — though resistance has reduced its utility
- Chlamydia trachomatis infections (urethritis, cervicitis)
- Pelvic Inflammatory Disease (PID) — used in combination regimens
3. Respiratory Tract Infections
- Community-acquired pneumonia (CAP)
- Chronic bronchitis exacerbations
- Active against Streptococcus pneumoniae, atypicals (Mycoplasma, Chlamydophila, Legionella)
4. Skin and Soft Tissue Infections
- Uncomplicated skin infections due to susceptible organisms
5. Ophthalmic Uses (Ofloxacin Eye Drops)
- Bacterial conjunctivitis
- Corneal ulcers (bacterial keratitis)
- Pre/post-operative ocular prophylaxis
6. Otic Uses (Ofloxacin Ear Drops)
- Otitis externa (swimmer's ear)
- Chronic suppurative otitis media (CSOM) with perforated tympanic membrane
- Otitis media in children with tympanostomy tubes
7. Tuberculosis (MDR-TB) — Off-label / Investigational
- Used in multidrug-resistant TB (MDR-TB) regimens based on in vitro efficacy and observational data (Treatment of Drug-Resistant Tuberculosis, p. 21)
- Not currently approved by regulatory authorities for TB, but levofloxacin (its L-isomer) is preferred in modern MDR-TB guidelines
8. Enteric Infections
- Typhoid fever (Salmonella typhi) — though resistance is rising
- Traveler's diarrhea
9. Leprosy (off-label)
- Part of combination regimens for multibacillary leprosy (WHO regimen alternatives)
Spectrum of Activity
| Category | Organisms Covered |
|---|---|
| Gram-negative | E. coli, Klebsiella, Proteus, Pseudomonas (limited), Haemophilus |
| Gram-positive | Staphylococcus aureus (MSSA), S. pneumoniae |
| Atypicals | Mycoplasma, Chlamydia, Legionella |
| Mycobacteria | M. tuberculosis (in vitro), M. leprae |
Dosage Forms
- Oral tablets: 200 mg, 400 mg
- IV infusion: for severe infections
- Ophthalmic solution: 0.3%
- Otic solution: 0.3%
Typical Oral Doses
| Indication | Dose |
|---|---|
| UTI (uncomplicated) | 200 mg twice daily × 3–7 days |
| UTI (complicated) / Prostatitis | 200–400 mg twice daily × 6–12 weeks |
| PID | 400 mg twice daily × 14 days (+ metronidazole) |
| Pneumonia | 400 mg twice daily × 10 days |
| Gonorrhea | 400 mg single dose |
Key Adverse Effects
- Tendinopathy / tendon rupture (including Achilles tendon) — especially in elderly and corticosteroid users
- QT prolongation — avoid with other QT-prolonging drugs
- Photosensitivity
- CNS effects — headache, dizziness, seizures (rare)
- Peripheral neuropathy
- Hepatotoxicity (rare)
- C. difficile-associated diarrhea
Contraindications / Cautions
- Children and adolescents <18 years (risk of cartilage damage — except otic/ophthalmic forms)
- Pregnancy and lactation
- History of fluoroquinolone-associated tendinopathy
- Myasthenia gravis (may worsen neuromuscular blockade)
- Epilepsy (lowers seizure threshold)
Note: In many countries, ofloxacin has been largely replaced by its more potent L-isomer levofloxacin for systemic indications. However, ofloxacin remains widely used in ophthalmic and otic formulations, and in certain regions for STIs and UTIs.
Tab fenofibrate dosing
Medical Text Search
fenofibrate tablet dosing dosage regimen
GradeResponse
Based on established pharmacology and clinical guidelines, here is a comprehensive overview of Tablet Fenofibrate Dosing:
Fenofibrate — Tablet Dosing
Drug Class
Fibric acid derivative (fibrate) — activates PPARα, reducing triglycerides and increasing HDL-C.
Available Formulations & Doses
| Formulation | Available Strengths |
|---|---|
| Fenofibrate tablets (standard) | 48 mg, 54 mg, 107 mg, 145 mg, 160 mg |
| Fenofibrate micronized capsules | 67 mg, 134 mg, 200 mg |
| Fenofibric acid (active metabolite) | 35 mg, 105 mg |
Note: Formulations are not interchangeable on a mg-per-mg basis due to differences in bioavailability.
Standard Dosing by Indication
| Indication | Dose | Frequency |
|---|---|---|
| Hypertriglyceridemia | 48–145 mg (tablet) or 67–200 mg (micronized) | Once daily |
| Mixed dyslipidemia / Hypercholesterolemia | 145 mg (tablet) or 200 mg (micronized) | Once daily |
| Hypertriglyceridemia (severe) | 145 mg tablet or 200 mg micronized | Once daily (max dose) |
- Maximum dose: 145 mg/day (standard tablet) or 200 mg/day (micronized)
- Older standard tablets (54 mg): dose is 54–160 mg/day
Administration
- With or without food — newer micronized and nanocrystal formulations (e.g., Tricor 145 mg, Fenoglide 120 mg) can be taken without food
- Older non-micronized formulations should be taken with meals to improve absorption
- Swallow whole; do not crush
Dose Adjustments
Renal Impairment
| CrCl / eGFR | Recommended Dose |
|---|---|
| >50 mL/min | Normal dose |
| 30–50 mL/min | Reduce to 48 mg/day (standard) or 67 mg/day (micronized) |
| <30 mL/min | Contraindicated |
| Dialysis | Contraindicated |
Hepatic Impairment
- Contraindicated in active liver disease or unexplained persistent liver function abnormalities
Elderly
- Start at lower end of dosing range; monitor renal function
Monitoring
- Lipid panel: at baseline, then at 4–8 weeks, then every 3–6 months
- LFTs: baseline; discontinue if AST/ALT >3× ULN
- CK: if myopathy symptoms develop
- SCr/eGFR: periodic monitoring (especially with statin combination)
- CBC: fenofibrate can rarely cause agranulocytosis
Key Drug Interactions
| Drug | Interaction |
|---|---|
| Statins | Increased risk of myopathy/rhabdomyolysis (especially gemfibrozil > fenofibrate) |
| Warfarin | Potentiates anticoagulant effect — reduce warfarin dose, monitor INR closely |
| Cyclosporine | Increased risk of nephrotoxicity; use caution |
| Bile acid sequestrants | Separate administration by ≥1 hour before or 4–6 hours after fenofibrate |
| Colchicine | Increased risk of myopathy |
Contraindications
- Severe renal impairment (CrCl <30 mL/min)
- Active liver disease / hepatic impairment
- Gallbladder disease (fenofibrate increases cholesterol excretion into bile → gallstones)
- Hypersensitivity to fenofibrate
- Breastfeeding
Adverse Effects
- GI: nausea, dyspepsia, abdominal pain (most common)
- Hepatotoxicity: elevated transaminases (dose-dependent, usually reversible)
- Myopathy / rhabdomyolysis: rare but serious
- Cholelithiasis (gallstones)
- Pancreatitis (paradoxical — rare, especially with severe hypertriglyceridemia)
- Hypersensitivity reactions
Clinical Pearls
- Fenofibrate is preferred over gemfibrozil when combining with a statin (lower myopathy risk)
- Most effective for hypertriglyceridemia (reduces TG by 30–50%) and raising HDL (by 10–20%); modest LDL-lowering effect
- Cardiovascular outcome benefit is primarily seen in patients with combined dyslipidemia (high TG + low HDL), especially in diabetic patients (FIELD and ACCORD trials)
- Allow 4–8 weeks to assess lipid response before adjusting dose
What treatment should be advise?
Medical Text Search
mixed dyslipidemia treatment guidelines statin high triglycerides high LDL
Medical Text Search
dyslipidemia management women lifestyle modifications pharmacotherapy
GradeResponse
GradeResponse
Lipid Profile Analysis — Mrs. Sunita, 48F
Lab Results Summary
| Parameter | Result | Reference | Status |
|---|---|---|---|
| Serum Cholesterol | 242.52 mg/dL | <200 | 🔴 HIGH |
| Serum Triglycerides | 246.33 mg/dL | 50–150 | 🔴 HIGH |
| HDL Cholesterol | 60.63 mg/dL | 30–95 | ✅ Normal |
| LDL Cholesterol | 132.63 mg/dL | <150 | ✅ Borderline |
| VLDL Cholesterol | 49.26 mg/dL | 14–45 | 🔴 HIGH |
| Cholesterol/HDL ratio | 4 | <4.5 | ✅ Normal |
| LDL/HDL ratio | 2.18 | <3.0 | ✅ Normal |
| HDL/LDL ratio | 0.45 | >0.2 | ✅ Normal |
Interpretation
This is Mixed Dyslipidemia (elevated total cholesterol + elevated triglycerides + elevated VLDL). HDL is satisfactory and LDL is borderline. The primary concerns are:
- Hypertriglyceridemia (TG 246 mg/dL)
- Hypercholesterolemia (Total cholesterol 242 mg/dL)
- Elevated VLDL (reflects TG burden)
At age 48, this woman may be perimenopausal, which independently worsens lipid profiles.
Recommended Treatment
Step 1 — Lifestyle Modifications (Mandatory, First-line)
(NLA Expert Panel — Patient-Centered Management of Dyslipidemia, p. 7)
- Diet: Reduce saturated fats (<7% of total energy), eliminate trans fats, increase omega-3 rich foods (fish, flaxseed), reduce refined carbohydrates and sugars (major driver of hypertriglyceridemia)
- Exercise: Aerobic exercise ≥150 min/week (brisk walking, cycling) — significantly lowers TG
- Weight loss: If overweight/obese — even 5–10% body weight loss improves TG markedly
- Alcohol restriction: Alcohol is a major cause of hypertriglyceridemia
- Reduce simple sugars: White rice, sweets, fruit juices, sugary drinks raise TG
Step 2 — Pharmacotherapy
Given Total Cholesterol + TG both elevated (mixed dyslipidemia), treatment should address both:
Option A — Statin alone (if cardiovascular risk is low)
| Drug | Dose | Effect |
|---|---|---|
| Rosuvastatin 10–20 mg OD at night | Preferred | ↓ LDL 40–50%, ↓ TG 10–20%, ↑ HDL |
| Atorvastatin 10–20 mg OD at night | Alternative | ↓ LDL 35–45%, ↓ TG 15–25% |
Atorvastatin has better TG-lowering among statins and is a good first choice here.
Option B — Statin + Fenofibrate (if TG remains >200 after statin, or high CV risk)
(Management of Dyslipidemia and Prevention of Cardiovascular Disease, p. 40)
- Tab Atorvastatin 10–20 mg at night +
- Tab Fenofibrate 145 mg (micronized) once daily with breakfast
This combination addresses both elevated cholesterol (statin) and hypertriglyceridemia (fenofibrate). Fenofibrate is preferred over gemfibrozil when combining with a statin (safer myopathy profile).
Suggested Prescription (Practical)
| Drug | Dose | Timing |
|---|---|---|
| Tab Atorvastatin 10 mg | Once daily | At night |
| Tab Fenofibrate 145 mg | Once daily | Morning with food |
| Cap Omega-3 fatty acids 1g | Once or twice daily | With meals (adjunct for TG) |
Monitoring (Follow-up at 6–8 weeks)
- Fasting lipid profile — reassess TG and LDL
- LFTs (baseline before starting statin + fenofibrate)
- CK if myalgia develops
- Blood glucose — statins mildly increase diabetes risk; important at age 48 (perimenopausal)
- TSH — hypothyroidism is a reversible secondary cause of dyslipidemia; must rule out
- Fasting blood sugar / HbA1c — diabetes is a major secondary cause of hypertriglyceridemia
Additional Workup to Consider
- TSH — hypothyroidism → dyslipidemia
- Fasting blood sugar / HbA1c — diabetes → hypertriglyceridemia
- Serum uric acid — often elevated with hypertriglyceridemia
- Renal function (if starting fenofibrate)
⚠️ Clinical Note: Final treatment decisions should be individualized based on cardiovascular risk assessment (presence of diabetes, hypertension, smoking, family history of CVD), menopausal status, and comorbidities. LDL target depends on the patient's overall ASCVD risk category.
This is a shared conversation. Sign in to Orris to start your own chat.